MA40904A - Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie - Google Patents

Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie

Info

Publication number
MA40904A
MA40904A MA040904A MA40904A MA40904A MA 40904 A MA40904 A MA 40904A MA 040904 A MA040904 A MA 040904A MA 40904 A MA40904 A MA 40904A MA 40904 A MA40904 A MA 40904A
Authority
MA
Morocco
Prior art keywords
cytopenia
duration
treating
reducing
methods
Prior art date
Application number
MA040904A
Other languages
English (en)
Inventor
Zheng Tao Han
Original Assignee
Hygeia Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hygeia Tech Inc filed Critical Hygeia Tech Inc
Publication of MA40904A publication Critical patent/MA40904A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Peptides Or Proteins (AREA)
MA040904A 2014-11-03 2015-11-02 Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie MA40904A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462074133P 2014-11-03 2014-11-03

Publications (1)

Publication Number Publication Date
MA40904A true MA40904A (fr) 2017-09-12

Family

ID=54479028

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040904A MA40904A (fr) 2014-11-03 2015-11-02 Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie

Country Status (17)

Country Link
US (3) US11260041B2 (fr)
EP (1) EP3215177B1 (fr)
JP (1) JP6755865B2 (fr)
KR (1) KR102527457B1 (fr)
CN (2) CN114887038A (fr)
AU (1) AU2015343375B2 (fr)
BR (1) BR112017009237A2 (fr)
CA (1) CA2965848A1 (fr)
IL (2) IL285900B2 (fr)
MA (1) MA40904A (fr)
MX (2) MX392097B (fr)
MY (1) MY185869A (fr)
PH (1) PH12017500814A1 (fr)
RU (2) RU2730998C2 (fr)
SG (3) SG10201911605TA (fr)
TW (1) TWI725947B (fr)
WO (1) WO2016073416A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
CN108653265A (zh) * 2018-04-26 2018-10-16 五邑大学 一种复合抗癌药物
CN114786697A (zh) * 2019-09-24 2022-07-22 K-Gen股份有限公司 作用于蛋白激酶c(pkc)的二萜类化合物
KR102178075B1 (ko) * 2020-07-31 2020-11-13 (주)쓰리에이씨 마스크 수명 인디케이터 및 이를 포함하는 마스크

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
AU5277902A (en) * 1995-03-03 2002-08-15 Trustees Of Boston University Compositions for the treatment of blood disorders
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US7407026B2 (en) * 2000-10-11 2008-08-05 Ford Global Technologies, Llc Control system for a hybrid electric vehicle to anticipate the need for a mode change
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
CA2501936A1 (fr) * 2002-10-15 2004-04-29 Celgene Corporation Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplastiques
RS54988B1 (sr) * 2007-01-31 2016-11-30 Biosuccess Biotech Company Preparati i metode za upotrebu estara forbola
US9636317B2 (en) * 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US11564901B2 (en) * 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
EA023344B1 (ru) * 2009-01-16 2016-05-31 Тева Фармасьютикал Индастриз Лтд. Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
SG11201404212YA (en) * 2012-01-18 2014-10-30 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters for the treatment of stroke

Also Published As

Publication number Publication date
SG11201703530TA (en) 2017-05-30
JP2017534632A (ja) 2017-11-24
MY185869A (en) 2021-06-14
SG10201903942UA (en) 2019-05-30
RU2017119183A (ru) 2018-12-05
CN114887038A (zh) 2022-08-12
IL251937B (en) 2021-09-30
TW201630597A (zh) 2016-09-01
IL285900B (en) 2022-11-01
KR20170072347A (ko) 2017-06-26
BR112017009237A2 (pt) 2017-12-26
MX2022001377A (es) 2022-04-01
US20170224648A1 (en) 2017-08-10
US20220133675A1 (en) 2022-05-05
US11260041B2 (en) 2022-03-01
TWI725947B (zh) 2021-05-01
RU2730998C2 (ru) 2020-08-26
SG10201911605TA (en) 2020-01-30
NZ731599A (en) 2021-04-30
WO2016073416A1 (fr) 2016-05-12
CN107206053A (zh) 2017-09-26
CN107206053B (zh) 2022-06-07
MX392097B (es) 2025-03-21
RU2017119183A3 (fr) 2019-05-16
IL285900A (en) 2021-09-30
CA2965848A1 (fr) 2016-05-12
IL285900B2 (en) 2023-03-01
IL251937A0 (en) 2017-06-29
JP6755865B2 (ja) 2020-09-16
KR102527457B1 (ko) 2023-04-28
HK1244203A1 (zh) 2018-08-03
MX2017005499A (es) 2017-08-04
EP3215177B1 (fr) 2022-05-11
PH12017500814A1 (en) 2017-10-02
EP3215177A1 (fr) 2017-09-13
RU2020125187A (ru) 2020-08-27
AU2015343375B2 (en) 2021-07-01
US20160120836A1 (en) 2016-05-05
AU2015343375A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
EP3359693A4 (fr) Procédés et compositions pour enrichissement de produits d'amplification
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP3359523A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
MA41044A (fr) Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3634424A4 (fr) Compositions et procédés pour prévenir ou traiter des affections musculaires
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
EP3512351A4 (fr) Compositions et procédés d'amélioration de goût d'édulcorants non nutritifs
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
IL285900A (en) Phorbol ester preparations and methods for treating cytopenia or reducing its duration
EP3426349A4 (fr) Procédés et compositions pour inhiber l'expression de pmp22
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3364986A4 (fr) Compositions de plasma et leurs procédés d'utilisation